Real-time funding, M&A, exec moves & hiring — the signals that move deals
The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Lyra Therapeutics, Inc.
480biomedical.comAI Executive Summary
AI-powered analysis of 8-K filing content
Lyra Therapeutics withdrew its appeal of a Nasdaq delisting determination, resulting in trading suspension on March 17, 2026 and subsequent delisting. This is a critical event that eliminates the company's public market access and severely impacts investor confidence and liquidity.
Key Takeaways
Lyra Therapeutics voluntarily withdrew its appeal against Nasdaq's delisting determination issued on February 2, 2026
Trading of common stock (ticker: LYRA) will be suspended on March 17, 2026, followed by Form 25 delisting notification to the SEC
2 more takeaways